Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Proviruses with identical sequences comprise a large fraction of the replication-competent HIV reservoir.

Bui JK, Sobolewski MD, Keele BF, Spindler J, Musick A, Wiegand A, Luke BT, Shao W, Hughes SH, Coffin JM, Kearney MF, Mellors JW.

PLoS Pathog. 2017 Mar 22;13(3):e1006283. doi: 10.1371/journal.ppat.1006283. eCollection 2017 Mar.

2.

Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG.

Alvarez RA, Maestre AM, Law K, Durham ND, Barria MI, Ishii-Watabe A, Tada M, Kapoor M, Hotta MT, Rodriguez-Caprio G, Fierer DS, Fernandez-Sesma A, Simon V, Chen BK.

JCI Insight. 2017 Feb 23;2(4):e88226. doi: 10.1172/jci.insight.88226.

3.
4.

Effective Cytotoxic T Lymphocyte Targeting of Persistent HIV-1 during Antiretroviral Therapy Requires Priming of Naive CD8+ T Cells.

Smith KN, Mailliard RB, Piazza PA, Fischer W, Korber BT, Fecek RJ, Ratner D, Gupta P, Mullins JI, Rinaldo CR.

MBio. 2016 May 31;7(3). pii: e00473-16. doi: 10.1128/mBio.00473-16. Erratum in: MBio. 2016;7(4). pii: e01012-16. doi: 10.1128/mBio.01012-16.

5.

Notwithstanding Circumstantial Alibis, Cytotoxic T Cells Can Be Major Killers of HIV-1-Infected Cells.

Gadhamsetty S, Coorens T, de Boer RJ.

J Virol. 2016 Jul 27;90(16):7066-83. doi: 10.1128/JVI.00306-16. Print 2016 Aug 15.

6.

Kill: boosting HIV-specific immune responses.

Trautmann L.

Curr Opin HIV AIDS. 2016 Jul;11(4):409-16. doi: 10.1097/COH.0000000000000286.

7.

HIV-specific CD8⁺ T cells and HIV eradication.

Jones RB, Walker BD.

J Clin Invest. 2016 Feb;126(2):455-63. doi: 10.1172/JCI80566. Epub 2016 Jan 5. Review.

8.

Initiation of Antiretroviral Therapy (ART) at Different Stages of HIV-1 Disease Is Not Associated with the Proportion of Exhausted CD8+ T Cells.

Jensen SS, Fomsgaard A, Larsen TK, Tingstedt JL, Gerstoft J, Kronborg G, Pedersen C, Karlsson I.

PLoS One. 2015 Oct 1;10(10):e0139573. doi: 10.1371/journal.pone.0139573. eCollection 2015.

9.

Reactivation Kinetics of HIV-1 and Susceptibility of Reactivated Latently Infected CD4+ T Cells to HIV-1-Specific CD8+ T Cells.

Walker-Sperling VE, Cohen VJ, Tarwater PM, Blankson JN.

J Virol. 2015 Sep;89(18):9631-8. doi: 10.1128/JVI.01454-15. Epub 2015 Jul 15.

10.

Can HIV-1-Specific ADCC Assist the Clearance of Reactivated Latently Infected Cells?

Lee WS, Parsons MS, Kent SJ, Lichtfuss M.

Front Immunol. 2015 May 27;6:265. doi: 10.3389/fimmu.2015.00265. eCollection 2015. Review. No abstract available.

11.

HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial.

Ensoli F, Cafaro A, Casabianca A, Tripiciano A, Bellino S, Longo O, Francavilla V, Picconi O, Sgadari C, Moretti S, Cossut MR, Arancio A, Orlandi C, Sernicola L, Maggiorella MT, Paniccia G, Mussini C, Lazzarin A, Sighinolfi L, Palamara G, Gori A, Angarano G, Di Pietro M, Galli M, Mercurio VS, Castelli F, Di Perri G, Monini P, Magnani M, Garaci E, Ensoli B.

Retrovirology. 2015 Apr 29;12:33. doi: 10.1186/s12977-015-0151-y.

12.

Acyclovir Therapy Reduces the CD4+ T Cell Response against the Immunodominant pp65 Protein from Cytomegalovirus in Immune Competent Individuals.

Pachnio A, Begum J, Fox A, Moss P.

PLoS One. 2015 Apr 29;10(4):e0125287. doi: 10.1371/journal.pone.0125287. eCollection 2015.

13.

Preserving HIV-specific T cell responses: does timing of antiretroviral therapy help?

Macatangay BJ, Rinaldo CR.

Curr Opin HIV AIDS. 2015 Jan;10(1):55-60. doi: 10.1097/COH.0000000000000124. Review.

14.

Comparative analysis of the capacity of elite suppressor CD4+ and CD8+ T cells to inhibit HIV-1 replication in monocyte-derived macrophages.

Walker-Sperling VE, Buckheit RW 3rd, Blankson JN.

J Virol. 2014 Sep 1;88(17):9789-98. doi: 10.1128/JVI.00860-14. Epub 2014 Jun 18.

15.

The Significance of Interferon-γ in HIV-1 Pathogenesis, Therapy, and Prophylaxis.

Roff SR, Noon-Song EN, Yamamoto JK.

Front Immunol. 2014 Jan 13;4:498. doi: 10.3389/fimmu.2013.00498. eCollection 2014 Jan 13. Review.

16.

Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques.

Vargas-Inchaustegui DA, Xiao P, Hogg AE, Demberg T, McKinnon K, Venzon D, Brocca-Cofano E, Dipasquale J, Lee EM, Hudacik L, Pal R, Sui Y, Berzofsky JA, Liu L, Langermann S, Robert-Guroff M.

Virology. 2013 Dec;447(1-2):274-84. doi: 10.1016/j.virol.2013.09.015. Epub 2013 Oct 9.

17.
18.

HIV-specific CD8+ T cells from elite controllers are primed for survival.

Yan J, Sabbaj S, Bansal A, Amatya N, Shacka JJ, Goepfert PA, Heath SL.

J Virol. 2013 May;87(9):5170-81. doi: 10.1128/JVI.02379-12. Epub 2013 Feb 28.

19.

Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection.

Paley MA, Kroy DC, Odorizzi PM, Johnnidis JB, Dolfi DV, Barnett BE, Bikoff EK, Robertson EJ, Lauer GM, Reiner SL, Wherry EJ.

Science. 2012 Nov 30;338(6111):1220-5. doi: 10.1126/science.1229620.

20.

Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.

Perez-Mazliah DE, Alvarez MG, Cooley G, Lococo BE, Bertocchi G, Petti M, Albareda MC, Armenti AH, Tarleton RL, Laucella SA, Viotti R.

J Antimicrob Chemother. 2013 Feb;68(2):424-37. doi: 10.1093/jac/dks390. Epub 2012 Oct 26.

Supplemental Content

Support Center